Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer

Colorectal cancer (CRC) is among the five most commonly diagnosed cancers worldwide, constituting 6% of all cancers and the third leading cause of cancer death. CRC is the third and second most frequent cancer in men and women worldwide, accounting for 14% and 13% of all cancer incidence rates, resp...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2019-08, Vol.307, p.108-138
Main Authors: Matos, Ana I., Carreira, Barbara, Peres, Carina, Moura, Liane I.F., Conniot, João, Fourniols, Thibaut, Scomparin, Anna, Martínez-Barriocanal, Águeda, Arango, Diego, Conde, João P., Préat, Véronique, Satchi-Fainaro, Ronit, Florindo, Helena F.
Format: Article
Language:English
Subjects:
Colorectal cancer
Combinational schemes
Immunotherapy
Nanotechnology
Tumor immune microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal cancer (CRC) is among the five most commonly diagnosed cancers worldwide, constituting 6% of all cancers and the third leading cause of cancer death. CRC is the third and second most frequent cancer in men and women worldwide, accounting for 14% and 13% of all cancer incidence rates, respectively. CRC incidence is decreasing in older populations, but it has been significantly rising worldwide in adolescents and adults younger than 50 years old. Significant advances in the screening methods and surgical procedures have been underlying the reduction of the CRC incidence rate in older populations. However, there is an urgent demand for the development of alternative effective therapeutic options to overcome advanced metastatic CRC, while preventing disease recurrence. This review addresses the immune and CRC biology, summarizing the recent advances on the immune and/or therapeutic regimens currently in clinical use. We will focus on the emerging role of nanotechnology in the development of combinational therapies targeting and thereby regulating the function of the major players in CRC progression and immune evasion. [Display omitted] •Colorectal cancer (CRC) is within the 5 most commonly diagnosed cancers worldwide.•Promising clinical development of immune and chemotherapeutic regimens against CRC.•Nanotechnology can improve CRC combinational chemo-immunotherapies.•Urgent need for the validation of models resembling a specific CRS disease stage.
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2019.06.017